Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
48.66
+0.31 (0.64%)
Feb 27, 2026, 4:00 PM EST - Market closed
Sanofi Employees
Sanofi had 74,846 employees as of December 31, 2025. The number of employees decreased by 8,032 or -9.69% compared to the previous year.
Employees
74,846
Change (1Y)
-8,032
Growth (1Y)
-9.69%
Revenue / Employee
$732,842
Profits / Employee
$122,564
Market Cap
117.29B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 74,846 | -8,032 | -9.69% |
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
| Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
| Dec 31, 2017 | 106,566 | -293 | -0.27% |
| Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
| Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
| Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
| Dec 31, 2013 | 112,128 | 154 | 0.14% |
| Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
| Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
| Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
| Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
| Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
| Dec 31, 2007 | 99,495 | -794 | -0.79% |
| Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
| Dec 31, 2005 | 97,181 | 742 | 0.77% |
| Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
| Dec 31, 2003 | 33,086 | 650 | 2.00% |
| Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
| Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
| Dec 31, 2000 | 29,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
| AbbVie | 57,000 |
| Bristol-Myers Squibb Company | 32,500 |
SNY News
- 1 day ago - Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expansion - GuruFocus
- 1 day ago - Regeneron, Sanofi Receive Positive CHMP Opinion For Dupixent In Pediatric CSU - Nasdaq
- 1 day ago - Sanofi (SNY): Positive EMA Opinion for Dupixent Approval in the EU - GuruFocus
- 1 day ago - Sanofi: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - Finanz Nachrichten
- 1 day ago - Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - Benzinga
- 1 day ago - Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - GlobeNewsWire
- 1 day ago - Sanofi's Acoziborole Receives Positive CHMP Opinion For Sleeping Sickness Treatment - Finanz Nachrichten
- 1 day ago - Sanofi: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness - Finanz Nachrichten